Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx
This observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.
Authors
- Gun Min Youn (ORCID: https://orcid.org/0000-0002-1873-7655)
- Vivian Yang (ORCID: https://orcid.org/0000-0001-9302-0403)
- Gordon H. Bae (ORCID: https://orcid.org/0000-0001-9996-4763)
- Joo Yeon Kim (ORCID: https://orcid.org/0000-0001-5899-8238)
Institutions
- University of California, San Francisco (US)
- Emergency University (US)
- Stanford University (US)
Publication Details
- Journal
- JMIR Dermatology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.2196/64300
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00